Page 58 - Read Online

Kalloo et al. Metab Target Organ Damage 2023;3:7 https://dx.doi.org/10.20517/mtod.2022.26 Page 19 of 19

without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Lancet 2021;398:583-98. DOI PubMed
73. Battelino T, Bergenstal RM, Rodríguez A, et al. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic
control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised,
open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 2022;10:407-17. DOI
74. Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á. Effect of tirzepatide versus insulin degludec on liver fat
content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label,
parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 2022;10:393-406. DOI PubMed
75. Available from: https://clinicaltrials.gov/ct2/show/NCT04166773 [Last accessed on 24 May 2023].
76. Parker VER, Robertson D, Wang T, et al. Efficacy, safety, and mechanistic insights of cotadutide, a dual receptor glucagon-like
peptide-1 and glucagon agonist. J Clin Endocrinol Metab 2020;105:803-20. DOI
77. Prato S, Kahn SE, Pavo I, et al. SURPASS-4 investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased
cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 2021;398:1811-24.
DOI PubMed
78. Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med
2022;28:591-8. DOI PubMed PMC
79. Available from: https://clinicaltrials.gov/ct2/show/NCT04255433 [Last accessed on 24 May 2023].
80. Gerstein HC, Hart R, Colhoun HM, et al. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. Lancet
Diabetes Endocrinol 2020;8:106-14. DOI PubMed
81. Strain WD, Frenkel O, James MA, et al. Effects of semaglutide on stroke subtypes in type 2 diabetes: post hoc analysis of the
randomized SUSTAIN 6 and PIONEER 6. Stroke 2022;53:2749-57. DOI PubMed PMC
82. Available from: https://clinicaltrials.gov/ct2/show/NCT04777396 [Last accessed on 24 May 2023].
83. Available from: https://clinicaltrials.gov/ct2/show/NCT05394519 [Last accessed on 24 May 2023].
84. Available from: https://clinicaltrials.gov/ct2/show/NCT03574597 [Last accessed on 24 May 2023].
85. Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N
Engl J Med 2022;387:205-16. DOI
86. Kuchay MS, Krishan S, Mishra SK, et al. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised
controlled trial (D-LIFT trial). Diabetologia 2020;63:2434-45. DOI
87. Newsome PN, Buchholtz K, Cusi K, et al; NN9931-4296 Investigators. A placebo-controlled trial of subcutaneous semaglutide in
nonalcoholic steatohepatitis. N Engl J Med 2021;384:1113-24. DOI
88. Available from: https://clinicaltrials.gov/ct2/show/NCT04822181 [Last accessed on 24 May 2023].
89. Available from: https://clinicaltrials.gov/ct2/show/NCT05013229 [Last accessed on 24 May 2023].
90. Heikkala E, Mikkola I, Jokelainen J, Timonen M, Hagnäs M. Multimorbidity and achievement of treatment goals among patients with
type 2 diabetes: a primary care, real-world study. BMC Health Serv Res 2021;21:964. DOI PubMed PMC
91. Chiang JI, Hanlon P, Li TC, et al. Multimorbidity, mortality, and HbA1c in type 2 diabetes: a cohort study with UK and Taiwanese
cohorts. PLoS Med 2020;17:e1003094. DOI PubMed PMC
92. Xie F, Chan JC, Ma RC. Precision medicine in diabetes prevention, classification and management. J Diabetes Investig 2018;9:998-
1015. DOI PubMed PMC
93. Available from: https://www.fda.gov/medical-devices/in-vitro-diagnostics/precision-medicine [Last accessed on 24 May 2023].
94. Nathan DM, Lachin JM, Balasubramanyam A, et al; GRADE Study Research Group. Glycemia reduction in type 2 diabetes - glycemic
outcomes. N Engl J Med 2022;387:1063-74. DOI
95. Tye SC, Denig P, Heerspink HJL. Precision medicine approaches for diabetic kidney disease: opportunities and challenges. Nephrol
Dial Transplant 2021;36:3-9. DOI PubMed PMC